|
KR102727059B1
(ko)
|
2015-02-16 |
2024-11-05 |
더 유니버서티 어브 퀸슬랜드 |
설포닐우레아와 관련 화합물 및 그 용도
|
|
CN113220116A
(zh)
|
2015-10-20 |
2021-08-06 |
奇跃公司 |
改变可穿戴设备用户输入模式的系统和方法及可穿戴系统
|
|
KR102438052B1
(ko)
|
2016-03-31 |
2022-08-29 |
매직 립, 인코포레이티드 |
포즈들 및 멀티-dof 제어기들을 사용하는 3d 가상 객체들과 상호작용들
|
|
CA3047336A1
(en)
|
2017-01-23 |
2018-07-26 |
Jecure Therapeutics, Inc. |
Chemical compounds as inhibitors of interleukin-1 activity
|
|
KR102857458B1
(ko)
|
2017-04-19 |
2025-09-09 |
매직 립, 인코포레이티드 |
웨어러블 시스템을 위한 멀티모달 임무 실행 및 텍스트 편집
|
|
US11465992B2
(en)
|
2017-07-07 |
2022-10-11 |
Inflazome Limited |
Sulfonamide carboxamide compounds
|
|
CN111094242B
(zh)
*
|
2017-07-24 |
2024-02-09 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
RS65492B1
(sr)
|
2017-07-24 |
2024-05-31 |
Novartis Ag |
Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
|
|
MX2020001776A
(es)
*
|
2017-08-15 |
2020-03-24 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
|
|
US11542255B2
(en)
|
2017-08-15 |
2023-01-03 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
|
|
WO2019034693A1
(en)
|
2017-08-15 |
2019-02-21 |
Inflazome Limited |
SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
EP3697758B1
(en)
|
2017-10-17 |
2022-07-06 |
Novartis AG |
Sulphonamides and compositions thereof for treating conditions associated with nlrp activity
|
|
US12221434B2
(en)
|
2017-11-09 |
2025-02-11 |
Inflazome Limited |
Sulfonamide carboxamide compounds
|
|
KR20200087759A
(ko)
|
2017-11-09 |
2020-07-21 |
인플라좀 리미티드 |
신규한 설폰아마이드 카복스아마이드 화합물
|
|
US12030879B2
(en)
|
2018-03-02 |
2024-07-09 |
Inflazome Limited |
Sulfonyl acetamides as NLRP3 inhibitors
|
|
WO2019166624A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
US11834433B2
(en)
|
2018-03-02 |
2023-12-05 |
Inflazome Limited |
Compounds
|
|
US12168653B2
(en)
|
2018-03-02 |
2024-12-17 |
Inflazome Limited |
Sulfonamide derivates as NLRP3 inhibitors
|
|
EP3759077A1
(en)
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Novel compounds
|
|
EP3759078A1
(en)
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Novel compounds
|
|
GB201803394D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
GB201803393D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166632A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
CR20200588A
(es)
|
2018-05-04 |
2021-06-24 |
Inflazome Ltd |
Compuestos novedosos
|
|
CN112654350A
(zh)
|
2018-07-03 |
2021-04-13 |
诺华股份有限公司 |
使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
|
|
EP3817815A1
(en)
|
2018-07-03 |
2021-05-12 |
Novartis AG |
Nlrp modulators
|
|
SG11202012159TA
(en)
|
2018-07-20 |
2021-01-28 |
Hoffmann La Roche |
Sulfonylurea compounds as inhibitors of interleukin-1 activity
|
|
EP3823974A1
(en)
|
2018-07-20 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Sulfonimidamide compounds as inhibitors of interleukin-1 activity
|
|
US12187702B2
(en)
|
2018-08-15 |
2025-01-07 |
Inflazome Limited |
Sulfonamideurea compounds
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
US20220387397A1
(en)
*
|
2018-10-24 |
2022-12-08 |
Novartis Ag |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
EP3880666B1
(en)
|
2018-11-13 |
2023-06-28 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
CN113015730A
(zh)
*
|
2018-11-13 |
2021-06-22 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
US20230059136A1
(en)
*
|
2018-11-16 |
2023-02-23 |
Novartis Ag |
The compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
EP3914583A1
(en)
*
|
2019-01-22 |
2021-12-01 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
CN114761383A
(zh)
*
|
2019-06-12 |
2022-07-15 |
诺瑟拉有限公司 |
磺酰胺衍生物及其用途
|
|
US20220378801A1
(en)
|
2019-06-21 |
2022-12-01 |
Ac Immune Sa |
Novel compounds
|
|
JP7595642B2
(ja)
*
|
2019-07-17 |
2024-12-06 |
ズーマゲン バイオサイエンシーズ エルティーディー |
Ｎｌｒｐ３モジュレーター
|
|
AU2020312800B2
(en)
|
2019-07-17 |
2026-04-23 |
Zomagen Biosciences Ltd |
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
|
|
CN114555609A
(zh)
*
|
2019-08-16 |
2022-05-27 |
英夫拉索姆有限公司 |
用作nlrp3抑制剂的大环磺酰胺衍生物
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
KR20220154165A
(ko)
|
2020-03-16 |
2022-11-21 |
조마젠 바이오사이언시즈 엘티디 |
Nlrp3 조절제
|
|
CN115551512A
(zh)
*
|
2020-03-19 |
2022-12-30 |
南洋理工大学 |
包含nlrp1炎性体激活抑制剂的化合物或组合物用于治疗人气道炎症的用途
|
|
CN115279739B
(zh)
*
|
2020-03-27 |
2025-07-22 |
尼科治疗有限公司 |
取代哒嗪化合物
|
|
CN111419842A
(zh)
*
|
2020-04-24 |
2020-07-17 |
南方医科大学南方医院 |
炎症小体抑制剂cy-09用于制备治疗非酒精性脂肪性肝炎的药物的用途
|
|
US12428391B2
(en)
|
2020-06-11 |
2025-09-30 |
Cisen Pharmaceutical Co., Ltd |
Dimethylsulfoximine derivative
|
|
MX2022014709A
(es)
|
2020-06-19 |
2022-12-16 |
Ac Immune Sa |
Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3).
|
|
WO2022022646A1
(zh)
*
|
2020-07-29 |
2022-02-03 |
南京明德新药研发有限公司 |
含硒五元杂芳环化合物
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
CA3218212A1
(en)
|
2021-04-28 |
2022-11-03 |
Astellas Pharma Inc. |
Substituted triazine compound
|
|
TW202319055A
(zh)
|
2021-07-21 |
2023-05-16 |
日商安斯泰來製藥股份有限公司 |
縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物
|
|
CN114213358A
(zh)
*
|
2021-12-22 |
2022-03-22 |
上海泰坦科技股份有限公司 |
一种2-溴-5-甲醛基噻唑的合成方法
|
|
CN118541366A
(zh)
|
2021-12-22 |
2024-08-23 |
Ac免疫有限公司 |
二氢噁唑衍生物化合物
|
|
JP2025524640A
(ja)
|
2022-07-14 |
2025-07-30 |
エーシー・イミューン・エス・アー |
Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
|
|
CA3261365A1
(en)
|
2022-07-28 |
2024-02-01 |
Ac Immune Sa |
NEW COMPOUNDS
|
|
JPWO2024090469A1
(https=)
|
2022-10-26 |
2024-05-02 |
|
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
PE20252770A1
(es)
*
|
2023-03-17 |
2025-12-22 |
Ventus Therapeutics U S Inc |
Derivados de amida para inhibir nlrp3 y usos de estos
|
|
KR20260027946A
(ko)
|
2023-06-02 |
2026-03-03 |
머크 샤프 앤드 돔 엘엘씨 |
Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
WO2025153532A1
(en)
|
2024-01-16 |
2025-07-24 |
NodThera Limited |
Nlrp3 inhibitors and glp-1 agonists combination therapies
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
WO2026057747A1
(en)
|
2024-09-11 |
2026-03-19 |
Ac Immune Sa |
Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
|